Patient-derived cell lines unveil COL1A2 as a predictor of docetaxel resistance in breast cancer
Our findings indicate that COL1A2 is associated with reduced chemotherapy sensitivity in HR+/HER2- breast cancer and may serve as a candidate biomarker to guide neoadjuvant taxane selection. This study provides a novel theoretical basis for optimizing neoadjuvant chemotherapy regimens in patients with advanced HR+/HER2- breast cancer.
Authors
- Jinting Liu (ORCID: https://orcid.org/0000-0003-2136-8560)
- Qingjun Gao
- Xiaowei Dou
- Rong Wang (ORCID: https://orcid.org/0000-0003-3502-5446)
- Jianjun Huang (ORCID: https://orcid.org/0000-0003-3755-1319)
- Suo Zhu
- Song Chen
- Wenhao Chen
- Yuwei Gao
Institutions
- Guiyang Medical University (CN)
- Anshun University (CN)
- Affiliated Hospital of Guizhou Medical University (CN)
- Breast Center (CH)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-03-02
- DOI
- https://doi.org/10.3389/fonc.2025.1737405
- Primary Topic
- Cancer Cells and Metastasis
- Type
- article
- Field-Weighted Citation Impact
- 0.00